Recent studies have centered on the overlap of GLP-1|glucose-dependent insulinotropic polypeptide|GCGR stimulant therapies and dopamine neurotransmission. While GCGR agonists are commonly employed for addressing type 2 diabetes mellitus, their unexpected effects on reward circuits, specifically mediated by dopaminergic networks, are gaining subs… Read More